Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Cocrystal Pharma, Inc. | Director | Common Stock | 1.02M | $2.02M | $1.97 | Oct 9, 2024 | Direct |
PRECIGEN, INC. | Director | Common Stock | 1.03M | $1.47M | $1.43 | Mar 14, 2024 | Direct |
PRECIGEN, INC. | Director | Restricted Stock Units | 87.4K | $125K | $1.43 | Mar 14, 2024 | Direct |
PRECIGEN, INC. | Director | Option to Purchase Common Stock (Right to Buy) | 102K | Mar 14, 2024 | Direct | ||
EyePoint Pharmaceuticals, Inc. | Director | Stock Options (Right to buy) | 60K | Sep 3, 2024 | Direct | ||
BridgeBio Pharma, Inc. | Director | Stock Option (Right to Buy) | 26K | Jun 21, 2024 | Direct | ||
Prometheus Biosciences, Inc. | Director | Common Stock | 0 | $108.42 | Jun 16, 2023 | Direct | |
Prometheus Biosciences, Inc. | Director | Stock Option (right to buy) | 0 | Jun 16, 2023 | Direct |